Objective To systematic review the clinical value of urine derived prostate cancer gene 3 (PCA3) scores for predicting the result of prostate biopsy during diagnosing the prostate cancer.Methods Articles related to the value of urine derived PCA3 score for forecasting the result of prostate biopsy during diagnosing the prostate cancer,published from inception to November 2013,were retrieved in the databanks including PubMed (1966-2013),CNKI (1979-2013),EMBASE(1988-2013),and Cochrane liberary.Meta-Disc 1.4 software was used to analyze data.According to the inclusion and exclusion criteria,the literatures were screened.And the quality of included literatures were evaluated.The pooled sensitivity,specificity,the likelihood ratio(LR) were calculated and summary receiver operating characteristic curve(SROC curve) was made.Results A total of 22 articles with 3 060 prostate cancer cases and 5 307 normal or BPH cases were included.Since there was heterogeneity between the studies,the data was calculated by the random effect model.The pooled sensitivity of PCA3 score was 63％ (95％CI:0.61-0.65) and the pooled specificity was 70％ (95％CI:0.69-0.72),respectively.The positive (P-LR) and negative likelihood ratio (N-LR) were 2.38 (95％CI:2.05-2.77) and 0.51 (95％CI:0.46-0.58),respectively.The diagnosis odds ratio (DOR) was 4.88 (95％ CI:3.83-6.21).Summary receiver operating characteristic curve area under curve (SROC AUC) was 0.7445,Q* index was 0.689,respectively.Conclusions The performance of urine derived PCA3 score has higher accuracy of detection than other method in the diagnosis of prostate cancer.It can be a novel and optional non-invasive test and an important adjunct test for predicting the result of prostate biopsy.

Objective To explore the relationship between the clinical features,serological markers and European League Against Rheumatism SS Disease Activity Index (ESSDAI) scores of primary Sj(o)gren's syndrome (SS).Methods We enrolled 106 patients,who fulfilled the 2002 classification criteria for primary SS from December 2008 to January 2015,to evaluate the relationship among the clinical characteristics,laboratory features,serological variables and ESSDAI scores.According to serological variables,the prognosis was subdivided into three distinct groups:favourable (no serological markers),intermediate (one serological marker) and poor (two or more serological markers).These data were analyzed by Chi-square test and variance analysis.Results The mean ESSDAI score of 106 pSS patients was (11±7).ESSDAI score was categorized according to the EULAR-SS recommendations as low activity,moderate activity and high activity (scores of 0-4,5-13 and ≥14,respectively),and the positive rate of antinuclear antibody (ANA) 1:100 (6 cases,37.5％;37 cases,66.1％;32 cases,94.1％) in three different ESSDAI levels was statistically different (x2＝18.110,P＜0.01).Those with positive ANA 1:100[positive (13±7) and negative (7±4)],anti-SSA antibody postive (12±7) and negative (9±7),anti-RNP antibody (positive 16±9 and negative 10±6) had higher ESSDAI scores than those with negative ones (F=8.812,P=0.0001;F=3.862,P=0.024;F=5.786,P=0.004).No statistical difference in ESSDAI means were found between patients with positive anti-SSB antibody,rheumatoid factor (RF),FS level,dry mouth,Raynoud's phenomenon and psychosomatic diseases.The ESSDAI scores of favourable group,intermediate group and poor group were significantly different (8±5,10±7,14±7,F=8.715,P=0.000 1).In comparison with the other two groups,the poor pSS patients had a higher frequency of positive ANA 1:100 (15 cases,55.6％;20 cases,57.1％;40 cases,90.9％),anti-SSA antibody(11 cases,0.7％;23 cases,41.1％;36 cases,81.8％),anti-SSB antibody (6 cases,2 2.2％;13 cases,37.1％;23 cases,52.3％),anti-RNP antibody (0 case,0;2 cases,5.7％;9 cases,20.5％) (x2=17.408,P=0.002;x2=14.306,P=0.006;x2=12.330,P=0.015;x2=1 1.482,P=0.022).Conclusion Patients with two or more serological markers may have higher ESSDAI score,and which in turn may associate with poor prognosis.

A 49-year-old woman was admitted with a three-month history of myalgia and progressive proximal and distal muscle weaknesses. Physical examination showed diffuse enlargement of the thyroid gland and mild muscle atrophy. Serum creatine kinase was slightly increased and electromyography showed a myopathic pattern. Muscle biopsy showed nonspecific myopathic changes. Serum thyroid-stimulating hormone was very low, whereas thyroxine (T4) was greatly increased as well as anti-thyroglobulin, anti-microsome, and TSH-receptor antibody. The patient's symptoms were improved during the treatment with propilthiouracil.
Biopsy ; Creatine Kinase ; Electromyography ; Female ; Graves Disease* ; Humans ; Hyperthyroidism ; Middle Aged ; Muscle Weakness ; Muscular Atrophy ; Muscular Diseases* ; Myalgia ; Physical Examination ; Thyroid Gland ; Thyrotropin ; Thyroxine